A clinical-stage biotech making vaccines with its XpressCF cell-free protein synthesis platform, which builds conjugate shots without the immune-dampening carrier proteins that limit conventional pneumococcal vaccines. Its lead candidates, VAX-31 and VAX-24, aim at pneumococcal disease in adults and children, and its pipeline also covers strep and shigellosis. The company gained control of its cell-free extract manufacturing through an agreement with Sutro Biopharma.
VAX-31 Phase 3 trial enrollment completed, setting up a pivotal Q4 2026 data readout as quarterly R&D spend reached $267.9M.
The VAX-31 adult Phase 3 program completed enrollment, putting the company on the cusp of its first pivotal data readout. The net loss widened to $284.3 million, or $1.97 per share, as R&D expenses rose 37.9% to $267.9 million to run the OPUS trials and build pre-launch . The entire investment case now rests on the topline immunogenicity data expected next quarter.
Key takeaways
Enrollment completed across the VAX-31 adult Phase 3 OPUS program, and management expects to report topline safety and immunogenicity data from the OPUS-1 study in the fourth quarter of 2026.
Research and development expenses rose 37.9% to $267.9 million, driven by a $25.4 million increase in clinical trial costs for the OPUS studies and a $23.2 million rise in product manufacturing costs for potential commercial launches.
The net loss widened to $284.3 million from $166.6 million in the same quarter a year earlier, as the $73.7 million increase in R&D was only partially offset by other income.
Section summaries
Management's Discussion and Analysis
Net loss widened to $284.3M in Q2 FY2026 driven by a 37.9% surge in R&D expenses for VAX-31 Phase 3 trials and pre-commercial manufacturing.
⌄
Research and development expenses rose 37.9% to $267.9M, primarily due to a $25.4M increase in clinical costs for the VAX-31 OPUS-1, OPUS-2, and OPUS-3 Phase 3 studies and a $23.2M rise in product manufacturing costs to support potential future commercial launches.
Other income, net fell 69.0% to $18.5 million, primarily from a $35.9 million reduction in foreign currency gains as the dollar strengthened against the Swiss Franc.
Cash, cash equivalents, and investments totaled $2.5 billion at quarter-end, bolstered by $601.8 million in net proceeds from a February 2026 public offering, against a free cash outflow of $236.8 million for the quarter.
The company disclosed that new U.S. tariff proposals on pharmaceutical imports could increase manufacturing costs, adding a fresh external risk to the supply chain.
What changed
The VAX-31 Phase 3 start, flagged across multiple prior filings after delays from mid-2025 to December 2025, did initiate in Q1 2026 and has now completed enrollment, resolving the timeline uncertainty that had been a recurring watch item.
The VAX-24 infant Phase 2 data, previously expected in Q1 2025 and then unreported through Q1 2026, is no longer mentioned; management now guides to VAX-31 infant Phase 2 data by mid-2027, signaling a shift in the infant program strategy.
The quarterly R&D expense run rate, watched as the Phase 3 program began, reached $267.9 million in Q2 2026, up from $194.6 million a year earlier and $312.8 million in Q1 2026, reflecting the full cost of running the pivotal trials and building pre-launch .
Foreign currency gains, which had provided a meaningful offset to operating losses in prior quarters, shrank to a $3.6 million gain from $38.5 million a year earlier, removing a that had cushioned the net loss.
A new risk factor on pharmaceutical import tariffs appeared for the first time, introducing a potential cost not present in any prior filing.
What to watch
Topline safety and immunogenicity data from the VAX-31 adult OPUS-1 Phase 3 study, expected in Q4 2026, which will determine whether the candidate can support a regulatory submission.
The quarterly R&D expense run rate now that enrollment is complete, to see whether spending declines from the Q2 2026 level of $267.9 million or remains elevated as manufacturing scale-up continues.
The impact of new U.S. pharmaceutical tariffs on manufacturing costs, given the company's reliance on a Swiss-based contract manufacturer for drug substance.
The VAX-31 infant Phase 2 study timeline, with data now guided to the first half of 2027, as the company builds its pediatric strategy around the broader-spectrum candidate.
Total other income, net fell 69.0% to $18.5M, mainly from a $35.9M reduction in and a $5.3M decrease in interest income due to lower cash balances and interest rates.
Net cash used in operating activities was $513.1M for the first half of 2026, up $225.7M , reflecting higher expenditures for PCV development and manufacturing scale-up.
The company strengthened its liquidity with $601.8M in net proceeds from a February 2026 follow-on public offering, ending the quarter with $2.5B in cash, cash equivalents, and investments.
Management expects to report topline Phase 3 data for the adult VAX-31 OPUS-1 trial in Q4 2026 and for the infant VAX-31 Phase 2 study by the end of the first half of 2027.
Quantitative and Qualitative Disclosures About Market Risk
Primary market risk is interest rate sensitivity on $2.5B in cash and investments, with foreign currency exposure from Swiss-franc obligations.
⌄
A hypothetical 10% increase in interest rates would increase net assets by $10.4M and reduce net loss by $5.0M for the six months ended June 30, 2026.
The company holds $2.5B in cash, equivalents, and investments, primarily in U.S. Treasury, agency, corporate debt, and money market instruments.
Foreign currency risk is concentrated in Swiss Franc exposures tied to a contract manufacturing organization in Switzerland, with no formal hedging program in place.
A hypothetical 10% adverse move in exchange rates would reduce net assets by $30.2M and increase net loss by $27.5M for the six months ended June 30, 2026.
Credit risk is managed through an investment policy that restricts instruments, credit ratings, maturities, and issuer concentration; the company believes a 10% change in credit rates would not be significant.
Inflation is noted as a potential risk to labor and R&D contract costs, but it did not materially affect results in the periods presented.
From time to time we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not presently a party to any legal proceedings that in the opinion of our management, if determined unfavorably to us, would have a materi…
⌄
From time to time we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not presently a party to any legal proceedings that in the opinion of our management, if determined unfavorably to us, would have a material adverse effect on our business, financial condition, operating results or cash flows. Regardless of the outcome, litigation can, among other things, be time consuming and expensive to resolve, and divert management resources.
Vaxcyte faces substantial risk as a clinical-stage biotech with no approved products, significant and growing losses, and heavy reliance on the success of its PCV candidates.
⌄
The company has no approved products, has incurred $2.8 billion in , and expects substantial and increasing operating losses for years, requiring significant additional capital.
The business is highly dependent on the success of its PCV candidates, particularly VAX-31, which faces risks of clinical failure, regulatory hurdles including a stricter standard, and intense competition from larger rivals.
Reliance on third-party manufacturers like Lonza and Thermo Fisher for clinical and commercial supply exposes the company to delays, capacity constraints, and compliance risks, with past manufacturing issues having already caused timeline setbacks.
The novel, unproven cell-free protein synthesis platform may face unforeseen development, manufacturing, or regulatory challenges, and no product using this platform has ever been FDA-approved.
Evolving federal vaccine policy, including potential changes to ACIP recommendations and new tariff proposals on pharmaceutical imports, introduces new uncertainties for market access, reimbursement, and manufacturing costs.
The company's intellectual property position is uncertain, facing risks from challenges to its patents, potential infringement claims, and dependence on in-licensed technologies that could be lost if agreements are breached.